New horizons for mortality risk stratification in PAD: Are targeted multiplex proteomics the next step?

Both morbidity and mortality of peripheral artery disease (PAD) remain unsatisfactory high with 113 all-cause death events per 1000 patient years, as depicted by a meta-analysis with data of the last two decades (1). Recent therapy improvements of traditional risk factors for PAD patients, like antiplatelet/anticoagulation therapy with Rivaroxaban (2) or further LDL-C lowering by PCSK9 inhibition (3) therapy might improve these numbers in meta-analyses in the next years. However, since traditional risk factors do not solely explain the high morbidity and mortality risk of PAD patients, as a model for traditional risk factors only generated an area-under the curve (AUC) of 0.65 (4) in a cohort of 1775 patients with PAD, novel horizons for risk stratification have to be evaluated.
Source: Atherosclerosis - Category: Cardiology Authors: Tags: Editorial Source Type: research